235 related articles for article (PubMed ID: 12148000)
1. Uncorking the biomanufacturing bottleneck.
Dove A
Nat Biotechnol; 2002 Aug; 20(8):777-9. PubMed ID: 12148000
[No Abstract] [Full Text] [Related]
2. The use of mushroom-forming fungi for the production of N-glycosylated therapeutic proteins.
Berends E; Scholtmeijer K; Wösten HA; Bosch D; Lugones LG
Trends Microbiol; 2009 Oct; 17(10):439-43. PubMed ID: 19758804
[TBL] [Abstract][Full Text] [Related]
3. Fermentation processes for prokaryotic cells.
Muth WL
Bioprocess Technol; 1991; 13():155-65. PubMed ID: 1367132
[No Abstract] [Full Text] [Related]
4. Mammalian cell culture capacity for biopharmaceutical manufacturing.
Ecker DM; Ransohoff TC
Adv Biochem Eng Biotechnol; 2014; 139():185-225. PubMed ID: 23748352
[TBL] [Abstract][Full Text] [Related]
5. Barnyard biotech--lame duck or golden goose?
Powell K
Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546
[No Abstract] [Full Text] [Related]
6. Biomanufacturing, from bust to boom...to bubble?
Thiel KA
Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
[No Abstract] [Full Text] [Related]
7. Biologicals production by recombinant DNA technology in Cuba.
Herrera L; Del la Fuente J; Quinones Y; Padron G; Agraz A; Vega J; Perez L; Silva A; Santizo C; Alvarez R
Dev Biol Stand; 1989; 70():257-69. PubMed ID: 2503409
[TBL] [Abstract][Full Text] [Related]
8. Industrialization of mAb production technology: the bioprocessing industry at a crossroads.
Kelley B
MAbs; 2009; 1(5):443-52. PubMed ID: 20065641
[TBL] [Abstract][Full Text] [Related]
9. The state of biopharmaceutical manufacturing.
Molowa DT; Mazanet R
Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
[TBL] [Abstract][Full Text] [Related]
10. Drug-making plant blooms.
Maxmen A
Nature; 2012 May; 485(7397):160. PubMed ID: 22575938
[No Abstract] [Full Text] [Related]
11. Immobilized animal cell bioreactors.
Croughan MS; Chiou TW; Wang DI
Bioprocess Technol; 1995; 21():377-411. PubMed ID: 7765642
[No Abstract] [Full Text] [Related]
12. Process analytical technology (PAT) for biopharmaceuticals.
Glassey J; Gernaey KV; Clemens C; Schulz TW; Oliveira R; Striedner G; Mandenius CF
Biotechnol J; 2011 Apr; 6(4):369-77. PubMed ID: 21416609
[No Abstract] [Full Text] [Related]
13. Bioreactor systems for the production of biopharmaceuticals from animal cells.
Warnock JN; Al-Rubeai M
Biotechnol Appl Biochem; 2006 Jul; 45(Pt 1):1-12. PubMed ID: 16764553
[TBL] [Abstract][Full Text] [Related]
14. A united front.
Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888
[No Abstract] [Full Text] [Related]
15. Plant molecular farming: systems and products.
Horn ME; Woodard SL; Howard JA
Plant Cell Rep; 2004 May; 22(10):711-20. PubMed ID: 14997337
[TBL] [Abstract][Full Text] [Related]
16. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production.
Walther J; Godawat R; Hwang C; Abe Y; Sinclair A; Konstantinov K
J Biotechnol; 2015 Nov; 213():3-12. PubMed ID: 26014522
[TBL] [Abstract][Full Text] [Related]
17. Biotechs go generic: the same but different.
Ledford H
Nature; 2007 Sep; 449(7160):274-6. PubMed ID: 17882194
[No Abstract] [Full Text] [Related]
18. Green factory: plants as bioproduction platforms for recombinant proteins.
Xu J; Dolan MC; Medrano G; Cramer CL; Weathers PJ
Biotechnol Adv; 2012; 30(5):1171-84. PubMed ID: 21924345
[TBL] [Abstract][Full Text] [Related]
19. Poor farmers warned against Internet transgenic crop deals.
Dalton R
Nature; 2003 Feb; 421(6925):776. PubMed ID: 12594471
[No Abstract] [Full Text] [Related]
20. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
